InvestaX Launches World’s 1st Digital SPACs
10.3.2021 05:29:00 EET | Business Wire | Press release
InvestaX, pioneers and creators of next generation technology driven investment products, announces the launch of the world’s first Digital SPACs, using smart contracts and blockchain technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309006112/en/
(Graphic: Business Wire)
InvestaX is a Singapore-headquartered and licensed platform for Digital Securities Offerings (DSOs) of global private markets deals, including venture, private equity & real estate.
Digital SPACs are going to play an integral role in providing necessary capital to growing companies in new industries and give investors access to unique and leading technology companies creating the infrastructure for the digital era.
InvestaX CEO, Julian Kwan, said, “InvestaX and partners, offer Digital SPACs targeting cryptocurrency infrastructure, blockchain and DLT start-ups, games and e-sports, space, robotics, AI, and other future looking industries that are reshaping the 21st century.”
Soul Capital Founder Billy So has built a successful tech portfolio of startups, many in the cryptocurrency industry, and is lead sponsor of the world’s 1st Digital SPAC.
Atlas One is the North America distribution partner.
Sponsors will accept cash or cryptocurrencies as investment, opening up a greater universe of investors and product offerings than traditional SPACs.
Digital SPACs will bring many similar elements of traditional SPACs, but offer a faster, lower cost, more flexible alternative, importantly bringing much needed capital to earlier stage start-ups in new industries, as well as greater transparency and better terms for investors.
Issuing a Digital SPAC using blockchain provides wider distribution channels for global investors who are prevented from, or prefer not to invest through traditional SPACs listed on USA stock exchanges. Digital SPACs will be distributed globally, not just domestically, opening up new markets and opportunities for sponsors and investors.
InvestaX will open source the smart contract code for the Digital SPAC, to bring greater openness, velocity, interoperability and global distribution. The average size of traditional SPACs in 2020 was approx. $350M USD making it challenging to find acquisition targets as the valuation range required is between $1-3BN USD. The first wave of Digital SPACs will target $10-50M USD, ensuring a much larger pool of potential acquisition targets and less competition for sponsors.
InvestaX provides key infrastructure to digitize real assets so you can use them to buy, sell, trade, borrow or lend instantly, across the world, 24x7.
Sign-up at www.investaX.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309006112/en/
Contact information
Julian Kwan
support@investaX.io
+65 9228 0994
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom